Qiagen Stock Price, News & Analysis

QIAGEN reported solid Q2 2024 performance, exceeding its outlook. Net sales reached $496 million, stable year-over-year but up 1% at constant exchange rates (CER). Adjusted diluted EPS was $0.55, surpassing the $0.52 CER outlook. The adjusted operating income margin improved to 28.4%, up from 27.4% in Q2 2023. Free cash flow increased 56% to $129 million.

Based on strong H1 2024 results, QIAGEN updated its FY 2024 outlook. The company now expects net sales of at least $1.985 billion CER, reflecting solid core business trends and the decision to phase out the NeuMoDx system. The adjusted diluted EPS outlook was raised to at least $2.16 CER, with an adjusted operating income margin target of at least 28.5%.

QIAGEN announced a partnership with the University of Montana's Snow Molecular Anthropology Lab to advance forensic services for identifying remains of missing and murdered Indigenous people (MMIP) and unidentified human remains (UHRs). The collaboration involves using DNA technologies, including next-generation sequencing (NGS) and forensic investigative genetic genealogy (FIGG). QIAGEN will provide the lab with MiSeq FGx sequencing systems, ForenSeq Kintelligence kits, and training. The partnership aims to build the first Indigenous-owned DNA database and identify the remains of 95 African American individuals discovered in Sugar Land, Texas. The collaboration underscores QIAGEN’s leadership in forensic applications, focusing on delivering accurate results and culturally sensitive practices. The initiative will also help families affected by the MMIP epidemic, using modern technologies to trace loved ones' identities while respecting cultural practices.

QIAGEN N.V. (NYSE: QGEN) will release its Q2 2024 financial results on July 31, 2024, just after 22:05 Frankfurt time, 21:05 London time, and 16:05 New York time. The company will hold a conference call discussing the results on August 1, 2024, at 15:00 Frankfurt time, 14:00 London time, and 09:00 New York time. Participants can join via a call-back service, dial-in by phone, or access an audio webcast. Registration for call-back and webcast access is available 15 minutes before the call starts. A replay of the conference call will be accessible via a web link.

QIAGEN announced the endorsement of its QuantiFERON-TB Gold Plus test by the American Academy of Pediatrics (AAP) for detecting latent tuberculosis (TB) in children of all ages. The AAP's new guidelines recommend using modern blood-based tests, such as IGRA, to screen at-risk children, emphasizing their accuracy and efficiency over traditional skin tests. This adjustment aligns with broader U.S. trends shifting towards improved TB control methods, especially important given the recent 16% increase in active TB cases in the U.S. The updated guidelines are expected to enhance early detection and treatment, preventing the progression to active TB disease.

QIAGEN announced its 2028 strategy at the Capital Markets Day in New York. The company targets about 7% compound annual sales growth (CAGR) at constant exchange rates (CER) from 2024-2028 and aims for a 31% CER adjusted operating income margin by 2028. This strategy includes significant investments in R&D and digital initiatives, streamlining the portfolio, and launching new products. QIAGEN also plans to return at least $1 billion to shareholders and pursue value-creating M&A opportunities. Key growth pillars include digital PCR, syndromic diagnosis, digital insights, sample technologies, and the QuantiFERON-TB Gold Plus test.

QIAGEN announced a new version of its clinical decision support software, QCI Interpret, tailored for high-throughput NGS labs. The update boosts performance, scalability, and user collaboration, significantly improving turnaround times, diagnostic yield, and result quality. Key features include bulk variant assessment, co-occurring variant flagging, and enhanced multi-user functionality. These enhancements address the growing demands of genomics labs, enabling seamless test expansion without compromising efficiency. The software, which processes over 850,000 clinical samples annually, now offers faster, more reliable variant analysis, and has received European IVDR certification as a Class C Medical Device.

QIAGEN has released its 2023 Sustainability Report, showcasing significant progress on its Environmental, Social, and Governance (ESG) commitments.

Key environmental achievements include a 15% reduction in Scope 1 and 2 emissions, primarily through increased green energy procurement, and a 7% reduction in plastic usage.

Socially, QIAGEN has expanded diagnostic access globally, committed to at least 40% female leadership by 2027, and achieved top scores for LGBTQ+ inclusion.

Governance improvements feature an updated Supplier Code of Conduct and the formation of a Human Rights Committee. ESG goals are incorporated into employee compensation, now representing 20% of annual variable pay.

QIAGEN's sustainability efforts have been recognized with high ratings from MSCI ESG Research, ISS-ESG, and Sustainalytics.

QIAGEN unveils 35 new digital PCR Microbial DNA Detection Assays for its QIAcuity platform, targeting pathogens behind tropical diseases, sexually transmitted infections (STIs), and urinary tract infections (UTIs). This expansion is part of a broader strategy to enhance microbial research, increasing QIAGEN's total microbial dPCR assay portfolio to over 680 targets. The assays offer high precision and sensitivity, supporting infectious disease research and public health efforts. QIAGEN will present these advancements at the ASM Microbe conference from June 13-17, 2024, in Atlanta.

QIAGEN (NYSE: QGEN) announced its decision to discontinue the NeuMoDx 96 and 288 Molecular Systems due to changing market dynamics post-COVID-19. This move aims to redirect resources towards more promising segments like the QIAstat-Dx system, QIAcuity digital PCR systems, and QIAGEN Digital Insights (QDI) bioinformatics. The company will support NeuMoDx customers during a transition period extending into 2025.

QIAGEN reaffirmed its Q2 2024 outlook with net sales of at least $495 million CER and adjusted diluted EPS of $0.52 CER. The full-year 2024 adjusted diluted EPS outlook is updated to $2.14 CER. A pre-tax restructuring charge of approximately $400 million, including $300 million in non-cash charges, will be recognized primarily in Q2 2024.

Discussions with NeuMoDx customers are ongoing to assess the impact on the projected 2024 sales of $55 million CER, with further details to be provided in Q2 2024 results.